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Background
Nanoparticle (NP)-based materials are very promising
agents for enhancing cancer diagnosis and treatment.
Once functionalized for selective targeting of tumor
expressed molecules, they can specifically deliver drugs
and diagnostic molecules inside tumor cells.
Materials and methods
In the present work, we evaluated the in vivo melanoma-
targeting ability of a nanovector (HFt-MSH-PEG) based
on human protein ferritin (HFt), functionalized with both
melanoma-targeting melanoma stimulating hormone
(a-MSH) and stabilizing poly(ethylene glycol) (PEG) mole-
cules. We used two independent and complementary tech-
niques, such as whole-specimen confocal microscopy and
magnetic resonance imaging, to detect the in vivo localiza-
tion of NP constructs endowed with suitable tracers
(i.e., fluorophores or magnetic metals).
Results
Targeted HFt-MSH-PEG NPs were shown to accumulate
persistently at the level of primary melanoma and with high
selectivity with respect to other organs. Melanoma localiza-
tion of untargeted HFt-PEG NPs, lacking the a-MSH moi-
ety, was less pronounced and disappeared after a few days.
Further, HFt-MSH-PEG NPs accumulated to a significantly
lower extent and with a different distribution in a diverse
type of tumor (TS/A adenocarcinoma), which does not
express a-MSH receptors. Finally, in a spontaneous lung
metastasis model, HFt-MSH-PEG NPs localized at the
metastasis level as well.
Conclusions
These results point at HFt-MSH-PEG NPs as suitable
carriers for selective in vivo delivery of diagnostic or
therapeutic agents to cutaneous melanoma.
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